CHAD Therapeutics Company Description
Finding the home oxygen market inhospitable, CHAD Therapeutics is looking for a friendlier reception as a sleep disorder company. It sold its oxygen conserver assets to Florida-based Inovo and some other oxygen equipment assets to Respironics; and it is using the money from the sales to pay off debt and develop devices for treating sleep disorders, a therapeutic category that includes conditions such as sleep apnea. Its oxygen conserver products, which it had been making since 1986, were devices that extended the life of home oxygen supplies for patients who require supplemental oxygen, usually those who suffer from emphysema and other chronic obstructive pulmonary diseases.
View the Comprehensive Company Description for CHAD Therapeutics
The Company Description provides a historical perspective of CHAD Therapeutics's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of CHAD Therapeutics's evolution in the marketplace.
